美国 - 英文 - NLM (National Library of Medicine)

novadoz pharmaceuticals llc - sirolimus (unii: w36zg6ft64) (sirolimus - unii:w36zg6ft64) - sirolimus oral solution is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. in patients at low-to moderate-immunologic risk , it is recommended that sirolimus oral solution be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn 2 to 4 months after transplantation [see dosage and administration (2.2) ]. in patients at high-immunologic risk (defined as black recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high panel-reactive antibodies [pra; peak pra level >80%]), it is recommended that sirolimus oral solution be used in combination with cyclosporine and corticosteroids for the first year following transplantation [see dosage and administration (2.3) , clinical studies (14.3) ]. cyclosporine withdrawal has not been studied in patients with banff grade 3 acute rejection or vascular rejection prior to cyclosporine withdrawa

比利时 - 德文 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare - temsirolimus - konzentrat und lösungsmittel zur herstellung einer infusionslösung - 30 mg - temsirolimus 25 mg/ml - temsirolimus

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - temsirolimus, quantity: 30 mg - injection, solution - excipient ingredients: polysorbate 80; macrogol 400; ethanol absolute - temsirolimus is indicated for the treatment of advanced renal cell carcinoma.,torisel is indicated for the treatment of advanced renal cell carcinoma. torisel is indicated for treatment of patients with relapsed and/or refractory mantle cell lymphoma.

美国 - 英文 - NLM (National Library of Medicine)

ax pharmaceutical corp - sirolimus (unii: w36zg6ft64) (sirolimus - unii:w36zg6ft64) -

美国 - 英文 - NLM (National Library of Medicine)

ax pharmaceutical corp - sirolimus (unii: w36zg6ft64) (sirolimus - unii:w36zg6ft64) -

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sirolimus, quantity: 0.5 mg - tablet, sugar coated - excipient ingredients: dl-alpha-tocopherol; iron oxide yellow; macrogol 8000; carnauba wax; iron oxide red; microcrystalline cellulose; purified talc; iron oxide black; povidone; magnesium stearate; macrogol 20000; shellac; sucrose; calcium sulfate; glyceryl monooleate; titanium dioxide; poloxamer; lactose monohydrate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; sulfuric acid - rapamune is indicated for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving renal transplants. therapeutic drug monitoring of sirolimus is required.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sirolimus, quantity: 2 mg - tablet, sugar coated - excipient ingredients: iron oxide red; shellac; dl-alpha-tocopherol; glyceryl monooleate; lactose monohydrate; macrogol 20000; calcium sulfate; titanium dioxide; iron oxide black; iron oxide yellow; magnesium stearate; povidone; macrogol 8000; microcrystalline cellulose; sucrose; carnauba wax; purified talc; poloxamer; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; sulfuric acid - for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving renal transplants. therapeutic drug monitoring of sirolimus is required.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sirolimus, quantity: 1 mg - tablet, sugar coated - excipient ingredients: titanium dioxide; magnesium stearate; purified talc; lactose monohydrate; carnauba wax; poloxamer; povidone; microcrystalline cellulose; dl-alpha-tocopherol; macrogol 20000; glyceryl monooleate; shellac; calcium sulfate; sucrose; macrogol 8000; propylene glycol; butan-1-ol; isopropyl alcohol; iron oxide red; strong ammonia solution; simethicone; ethanol; sulfuric acid - indications as at 9 february 2004: rapamune is indicated for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving renal transplants. therapeutic drug monitoring of sirolimus is required.

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - temsirolimus - concentrate and solvent for solution for infusion - 30 milligram(s) - protein kinase inhibitors; temsirolimus

美国 - 英文 - NLM (National Library of Medicine)

cardinal health - sirolimus (unii: w36zg6ft64) (sirolimus - unii:w36zg6ft64) - sirolimus 1 mg